Ars Pharmaceuticals CLO Alexander Fitzpatrick Sells $33,550 in Stock

Alexander A. Fitzpatrick, serving as the Chief Legal Officer at ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), completed a transaction involving the sale of the company's common stock on June 12, 2026. The financial scope of this divestment totaled $33,550. The details of this activity were formally disclosed through a recent Form 4 filing submitted to the Securities and Exchange Commission. The specific mechanics of the sale involved the disposal of 3,355 shares. Each share was transacted at a price point of $10.00. The execution of this trade was conducted in accordance with a Rule 10b5-1 trading plan. This particular plan was originally adopted by Fitzpatrick on December 5, 2025, establishing the framework for the subsequent sale activity. Post-transaction, the direct holdings of Fitzpatrick in ARS Pharmaceuticals common stock amount to 90,910 shares. The composition of these holdings includes specific acquisitions under the company's 2020 Employee Stock Purchase Plan (ESPP). On June 30, 2025, Fitzpatrick acquired 2,907 shares through this plan. An additional 1,745 shares were acquired under the same ESPP on December 31, 2025. The timing of this insider sale coincides with market activity where SPRY shares were trading at $9.75. This price point reflects a 14% return over the preceding week. ARS Pharmaceuticals holds a market valuation of $967 million. Financial metrics for the last twelve months indicate revenue generation of $99 million. Despite this revenue, the company remains unprofitable, reporting a net loss of $198 million. Analytical assessments from InvestingPro suggest that the stock may be slightly undervalued at current trading levels. Investors interested in detailed valuation models can access comprehensive Pro Research Reports for SPRY and over 1,400 other US equities. Recent corporate developments include the release of first-quarter 2026 earnings data. The report indicated a larger-than-expected loss per share alongside a slight revenue beat. The company posted an earnings per share (EPS) of -$0.61. This figure missed analyst expectations of -$0.49, resulting in a negative surprise of 24.49%. Conversely, revenue reached $22.7 million, slightly surpassing the forecasted amount of $22.67 million. Concurrently, Cantor Fitzgerald adjusted its outlook on ARS Pharmaceuticals. The firm raised its price target on SPRY shares to $30.00, an increase from the previous target of $12.00. The Overweight rating was maintained. This adjustment followed a detailed review of the company's clinical program addressing chronic spontaneous urticaria flares. Cantor Fitzgerald hosted a webinar to provide further insights into this program, following the release of a related report. Market data indicates SPRY closed at 9.75, representing a change of +0.16 or +1.67%. After-hours trading showed a price of 9.49, reflecting a change of -0.27 or -2.77%. The stock's performance is tracked across multiple timeframes including one day, one week, one month, six months, one year, five years, and maximum duration. The analysis underscores the intersection of insider trading activity, financial performance, and clinical program developments within the specialty pharmaceutical sector.